Alivus Life SciencesNSE:ALIVUS +2.01%83 Pretax Margin % is 31.32% as of Mar. 2026, which is 10% above its 10-year median of 28.54. GuruFocus rates NSE:ALIVUS with a GF Score™ of 83/100 and a GF Value™ of ₹1,005.96 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 954 Drug Manufacturers companies, Alivus Life Sciences ranks better than 91.19% on this metric.
The historical rank and industry rank for Alivus Life Sciences's Pretax Margin % or its related term are showing as below:
NSE:ALIVUS'
s Pretax Margin % Range Over the Past 10 Years
Min: 25.3 Med: 28.54 Max: 30.7
Current: 29.44
NSE:ALIVUS's Pretax Margin % is ranked better than 91.19% of 954
companies
in the Drug Manufacturers industry
Industry Median: 7.295
vs NSE:ALIVUS: 29.44
Alivus Life Sciences (NSE:ALIVUS) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Alivus Life Sciences Pretax Margin % Related Terms
Alivus Life Sciences Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Alivus Life Sciences's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ALIVUS vs ZTS, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alivus Life Sciences's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alivus Life Sciences Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alivus Life Sciences's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Alivus Life Sciences's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alivus Life Sciences (NSE:ALIVUS) has a Pretax Margin % of 31.32% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Alivus Life Sciences and its competitors. This is 10% above median its historical median of 28.54. Over the past decade, Alivus Life Sciences' Pretax Margin % has ranged from 25.30 to 30.70. According to the industry distribution chart, Alivus Life Sciences ranks #84 out of 954 companies in the Drug Manufacturers industry, placing it in the top 8.8%.
Is Alivus Life Sciences' Pretax Margin % too high?
Alivus Life Sciences' current Pretax Margin % of 31.32% is 10% above median its 10-year median of 28.54. Over the past 10 years, this metric has ranged from a low of 25.30 to a high of 30.70. The Drug Manufacturers industry median Pretax Margin % is 7.30. Alivus Life Sciences' value of 31.32% is 329.3% above this industry median. Based on the distribution chart, Alivus Life Sciences ranks #84 out of 954 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Alivus Life Sciences has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alivus Life Sciences' Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alivus Life Sciences ranks #84 out of 954 companies for Pretax Margin %. This places Alivus Life Sciences in the top 9% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.30. Alivus Life Sciences' value of 31.32% is 329.3% above this benchmark. Historically, Alivus Life Sciences' own Pretax Margin % has ranged from 25.30 to 30.70 over the past decade. While the company's 10-year median is 28.54 vs. the industry median of 7.30, Alivus Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alivus Life Sciences's current Pretax Margin % of 31.32% is 329.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Alivus Life Sciences and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alivus Life Sciences's current Pretax Margin % is 31.32%, which is 10% above median its own 10-year median of 28.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alivus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Alivus Life Sciences (NSE:ALIVUS) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,005.96, compared to a current price of ₹1,159.20 — trading 15.2% above its estimated fair value. The current Pretax Margin % is 31.32%, which is 10% above median its 10-year median of 28.54 and 329.3% above the Drug Manufacturers industry median of 7.30. Alivus Life Sciences' overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Alivus Life Sciences (NSE:ALIVUS), the current Pretax Margin % is 31.32% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alivus Life Sciences (NSE:ALIVUS) Overvalued in 2026?
Based on GuruFocus' analysis, Alivus Life Sciences stock appears to be overvalued.
The current stock price of ₹1,159.20 is trading 15.2% above its estimated GF Value™ of ₹1,005.96.
GuruFocus considers Alivus Life Sciences to be Modestly Overvalued.
Key valuation signals for NSE:ALIVUS:
Pretax Margin %: 31.32% (10% above median its 10-year median of 28.54)
GF Value™: ₹1,005.96 vs. price of ₹1,159.20 (15.2% above fair value)
Industry Position: 329.3% above the Drug Manufacturers median (#84 of 954)
No single metric tells the full story. See the NSE:ALIVUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
83GF Score
Get the complete analysis for NSE:ALIVUS
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ALIVUS has been successfully added to your 
